Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...
Oncologists want definitive guidance on whether patients with resectable NSCLC benefit from immunotherapy before and after ...
Merck to discontinue phase 3 KeyVibe-003 & KeyVibe-007 trials of vibostolimab and favezelimab FDCs with pembrolizumab in certain patients with NSCLC: Rahway, New Jersey Wednesday, ...
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...
Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and ...
Craig shouldn’t be alive to tell his story, in fact, he should have died three years ago, but a wonder drug dragged him back ...
Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...
Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritizing PYX-106 due to ...
During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, ...
Funds expected to be used to advance IO Biotech’s immune-modulating therapeutic cancer vaccines, including potential BLA submission for ...
The addition of atezolizumab to neoadjuvant chemotherapy failed to significantly improve event-free survival in patients with ...
The Company will focus resources on advancing its lead asset, PYX-201 - PYX-201 is a novel first-in-concept antibody-drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback